PRLD Key Statistics, Chart & Performance
The current stock price of PRLD is 1.46 USD. In the past month the price increased by 22.69%. In the past year, price increased by 82.5%.
PRLD Latest News, Press Relases and Analysis
PRLD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.61 | 394.34B | ||
| AMGN | AMGEN INC | 14.69 | 172.98B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.46 | 112.15B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.62 | 73.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 843.18 | 56.81B | ||
| INSM | INSMED INC | N/A | 41.92B | ||
| NTRA | NATERA INC | N/A | 33.00B | ||
| BIIB | BIOGEN INC | 10.78 | 26.47B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.17 | 20.65B | ||
| INCY | INCYTE CORP | 15.06 | 18.98B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.16B |
Related stock screener links
About PRLD
Company Profile
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 131 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Company Info
PRELUDE THERAPEUTICS INC
175 Innovation Boulevard
Wilmington DELAWARE 19803 US
CEO: Krishna Vaddi
Employees: 131
Phone: 13024671280
PRELUDE THERAPEUTICS INC / PRLD FAQ
What does PRLD do?
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 131 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
What is the stock price of PRELUDE THERAPEUTICS INC today?
The current stock price of PRLD is 1.46 USD.
Does PRLD stock pay dividends?
PRLD does not pay a dividend.
What is the ChartMill technical and fundamental rating of PRLD stock?
PRLD has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is PRELUDE THERAPEUTICS INC (PRLD) stock traded?
PRLD stock is listed on the Nasdaq exchange.
What is the analyst forecast for PRLD stock?
9 analysts have analysed PRLD and the average price target is 4.08 USD. This implies a price increase of 179.45% is expected in the next year compared to the current price of 1.46.
How is the valuation of PRELUDE THERAPEUTICS INC (PRLD) based on its PE ratio?
PRELUDE THERAPEUTICS INC (PRLD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.47).
PRLD Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PRLD. When comparing the yearly performance of all stocks, PRLD is one of the better performing stocks in the market, outperforming 94% of all stocks.
PRLD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PRLD. PRLD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PRLD Financial Highlights
Over the last trailing twelve months PRLD reported a non-GAAP Earnings per Share(EPS) of -1.47. The EPS increased by 16.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -134.21% | ||
| ROE | -217.26% | ||
| Debt/Equity | 0 |
PRLD Forecast & Estimates
9 analysts have analysed PRLD and the average price target is 4.08 USD. This implies a price increase of 179.45% is expected in the next year compared to the current price of 1.46.
For the next year, analysts expect an EPS growth of 24.65% and a revenue growth -100% for PRLD